Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiemetic |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:A04AD12
|
| gptkbp:CASNumber |
172673-20-0
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:eliminationHalfLife |
2.3 hours (fosaprepitant), 9-13 hours (aprepitant)
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C23H22F7N4O6P
|
| https://www.w3.org/2000/01/rdf-schema#label |
fosaprepitant
|
| gptkbp:KEGGID |
D04124
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Emend
|
| gptkbp:mechanismOfAction |
neurokinin-1 receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:prodrugOf |
gptkb:aprepitant
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
11523702 9709632 DB06717 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
constipation fatigue headache infusion site reactions |
| gptkbp:UNII |
6Y7TQ9N1TB
|
| gptkbp:usedFor |
prevention of chemotherapy-induced nausea and vomiting
|
| gptkbp:bfsParent |
gptkb:Aprepitant
|
| gptkbp:bfsLayer |
7
|